| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/19/2014 | EP2697227A1 Fused imidazole derivatives useful as ido inhibitors |
| 02/19/2014 | EP2697223A1 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| 02/19/2014 | EP2697222A1 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent |
| 02/19/2014 | EP2697221A1 N- cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists |
| 02/19/2014 | EP2697220A1 Chromenone compounds as pi 3 -kinase inhibitors for the treatment of cancer |
| 02/19/2014 | EP2697219A1 Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists |
| 02/19/2014 | EP2697217A1 Glycoside derivatives and their uses for the treatment of diabetes |
| 02/19/2014 | EP2697215A1 Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid |
| 02/19/2014 | EP2697213A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| 02/19/2014 | EP2697212A1 Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| 02/19/2014 | EP2697211A1 Process for preparing docetaxel and its hydrate |
| 02/19/2014 | EP2697210A1 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions, and their use |
| 02/19/2014 | EP2697208A1 1,3 oxazines as bace1 and/or bace2 inhibitors |
| 02/19/2014 | EP2697207A2 Cycloalkenyl aryl derivatives for cetp inhibitor |
| 02/19/2014 | EP2697206A1 Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| 02/19/2014 | EP2697205A1 Asymmetrically substituted anthrapyridazone derivatives as cytostatics |
| 02/19/2014 | EP2697203A1 Mineralocorticoid receptor antagonists |
| 02/19/2014 | EP2697201A2 N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide |
| 02/19/2014 | EP2697200A1 Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators |
| 02/19/2014 | EP2697199A1 Aryl-or heteroaryl-substituted benzene compounds |
| 02/19/2014 | EP2697198A1 Substituted benzene compounds |
| 02/19/2014 | EP2697197A1 Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (rorgamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| 02/19/2014 | EP2697196A1 Prodrugs of inhibitors of plasma kallikrein |
| 02/19/2014 | EP2697195A1 Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| 02/19/2014 | EP2697191A1 Branched 3-phenylpropionic acid derivatives and the use thereof |
| 02/19/2014 | EP2696937A1 Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors |
| 02/19/2014 | EP2696899A1 Polymer conjugated prostaglandin analogues |
| 02/19/2014 | EP2696890A1 Treatment of microbial infections |
| 02/19/2014 | EP2696886A2 C1q/tnf-related protein 12 and compositions and methods of using same |
| 02/19/2014 | EP2696879A1 Use of s-adenosylmethionine, vitamin e, and vitamin c for the prevention and treatment of cardiovascular dysfunction |
| 02/19/2014 | EP2696878A1 Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
| 02/19/2014 | EP2696877A1 Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| 02/19/2014 | EP2696876A1 Aqueous ophthalmic composition |
| 02/19/2014 | EP2696875A1 Methods for treating bacterial infection |
| 02/19/2014 | EP2696874A2 Compositions and methods for the treatment of nasal conditions |
| 02/19/2014 | EP2696873A2 Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
| 02/19/2014 | EP2696872A2 Treatment of glaucoma |
| 02/19/2014 | EP2696871A1 Aclidinium for use in improving the quality of sleep in respiratory patients |
| 02/19/2014 | EP2696870A1 Parp inhibitors for the treatment of cipn |
| 02/19/2014 | EP2696869A1 Methods for inhibiting allograft rejection |
| 02/19/2014 | EP2696868A1 Nutritional compositions including branched chain fatty acids and methods of using same |
| 02/19/2014 | EP2696867A1 Nutritional compositions including branched chain fatty acids for improving gut barrier function |
| 02/19/2014 | EP2696866A1 Nutritional compositions including branched chain fatty acids for wound healing |
| 02/19/2014 | EP2696865A2 N-acetyl beta alanine methods of use |
| 02/19/2014 | EP2696864A1 Therapeutic compounds |
| 02/19/2014 | EP2696863A1 Use of calixarenes associated with an antibiotic in the treatment of bacterial infections |
| 02/19/2014 | EP2696862A1 Use of calixarenes in the treatment of bacterial infections |
| 02/19/2014 | EP2696861A1 Combination of epa, dpa and/or dha with a chemotherapeutic agent |
| 02/19/2014 | EP2696860A2 Non human animal model for ulcerative colitis and its main complications |
| 02/19/2014 | EP2696859A1 Screening methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases |
| 02/19/2014 | EP2696858A2 Unit dose form for oral administration |
| 02/19/2014 | EP2696855A1 Coated mesoporous nanoparticles |
| 02/19/2014 | EP2696854A1 Febuxostat solid dispersion |
| 02/19/2014 | EP2696849A1 Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
| 02/19/2014 | EP2696844A1 Peptidyl arginine deiminase 1 and/or 3 activator compounds in the epidermis and uses thereof |
| 02/19/2014 | EP2696704A1 Process for the manufacture of a powder containing lutein |
| 02/19/2014 | EP2696692A1 Methods for regulating sirtuin gene expression |
| 02/19/2014 | EP2696684A1 Solid pharmaceutical composition |
| 02/19/2014 | EP2696683A1 Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
| 02/19/2014 | EP2696681A1 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| 02/19/2014 | EP2696680A1 Treatment of disease with poly-n-acety glucosamine nanofibers |
| 02/19/2014 | EP2696679A2 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| 02/19/2014 | EP2696678A1 Agents for improved delivery of nucleic acids to eukaryotic cells |
| 02/19/2014 | EP2696677A2 Cleaning, insecticide, insect repellant, glue solvent and anti-irritation composition |
| 02/19/2014 | CN203436580U Smooth slimming capsule structure capable of preventing and treating obesity and promoting micro-lipid metabolism |
| 02/19/2014 | CN1980637B Liposomes useful for drug delivery |
| 02/19/2014 | CN1350592B Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 02/19/2014 | CN103597075A Biologically active nucleotide molecules for selectively killing off cells, use thereof, and application kit |
| 02/19/2014 | CN103596961A Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
| 02/19/2014 | CN103596960A 6,7-dihydroimidazo [2, 1-b] [1, 3] oxazine bactericides |
| 02/19/2014 | CN103596958A Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds |
| 02/19/2014 | CN103596957A Imidazopyridazines as AKT kinase inhibitors |
| 02/19/2014 | CN103596956A Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or cyp3A4 inhibitors |
| 02/19/2014 | CN103596954A Polymorph of Linagliptin benzoate |
| 02/19/2014 | CN103596952A Substituted pyridopyrazines as novel Syk inhibitors |
| 02/19/2014 | CN103596951A 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer |
| 02/19/2014 | CN103596949A Compounds for treatment of metabolic syndrome |
| 02/19/2014 | CN103596948A Chromenone compounds as PI 3-kinase inhibitors for the treatment of cancer |
| 02/19/2014 | CN103596947A 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| 02/19/2014 | CN103596943A Hydantoin derivates as Kv3 inhibitors |
| 02/19/2014 | CN103596941A Anti-viral compounds |
| 02/19/2014 | CN103596940A Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant |
| 02/19/2014 | CN103596939A 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions, and their use |
| 02/19/2014 | CN103596938A 噻唑衍生物 Thiazole derivatives |
| 02/19/2014 | CN103596937A 取代的苯甲酰胺衍生物 Substituted benzamide derivatives |
| 02/19/2014 | CN103596933A Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as MGLU2 receptor agonist |
| 02/19/2014 | CN103596930A Pyrazole derivatives useful as aldosterone synthase inhibitors |
| 02/19/2014 | CN103596929A Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| 02/19/2014 | CN103596928A Neprilysin inhibitors |
| 02/19/2014 | CN103596926A Fused tricyclic compounds as RAF kinase inhibitors |
| 02/19/2014 | CN103596925A Benzo cycloheptene acetic acids |
| 02/19/2014 | CN103596922A Amino lipids, their synthesis and uses thereof |
| 02/19/2014 | CN103596594A Self-gelatinizable nucleic acid |
| 02/19/2014 | CN103596576A Platelet analysis system |
| 02/19/2014 | CN103596575A Gall wasp control agents |
| 02/19/2014 | CN103596574A SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
| 02/19/2014 | CN103596573A A method of managing hypercortisolemia, headache disorders, neuropathic pain and related disorders |
| 02/19/2014 | CN103596572A Aqueous ophthalmic composition |
| 02/19/2014 | CN103596571A Methods for treating insomnia |
| 02/19/2014 | CN103596570A Oxidosqualene cyclase as a protein target for anticancer therapeutics |